Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 8/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.64 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788536 | 0.91 | CACNA1I (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1786963 | 0.86 | NAMPT (0.52) | HDAC4KCNH2CACNA1IBCHE | |
| SCHEMBL7838832 | 0.84 | HDAC1 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1787915 | 0.83 | NAMPT (0.44) | KCNH2CACNA1IBCHE | |
| SCHEMBL7846422 | 0.83 | ACHE (0.76) | ACHEBCHE | |
| SCHEMBL1789513 | 0.82 | ROCK2 (0.49) | KCNH2CACNA1IBCHE | |
| SCHEMBL7945698 | 0.82 | SMYD3 (0.55) | KCNH2CACNA1IBCHE | |
| SCHEMBL1786901 | 0.82 | DRD2 (0.64) | ACHEDRD2DRD4BCHE | |
| SCHEMBL1790748 | 0.82 | KDM4E (0.54) | MEN1KMT2A | |
| SCHEMBL1789655 | 0.82 | HRH3 (0.48) | KCNH2CACNA1IBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | HDAC3 111/4885HDAC4 352/4885HDAC1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.